The prognostic value of tumor-associated macrophages in Non-Hodgkin's Lymphoma: A systematic review and meta-analysis.

Clicks: 436
ID: 11514
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #1 of 40 articles by views in scandinavian journal of immunology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Tumor-associated macrophages (TAMs) play an important role in the tumor environment, and were reported to be associated with poor prognosis in several tumors. However, the prognostic significance of TAMs in Non-Hodgkin's Lymphoma(NHL) remains controversial. Consequently, we aimed to evaluate the relationship between subpopulations of TAMs and clinical outcomes in NHL patients METHODS: We did a comprehensive search of the PubMed, ELSEVIER ScienceDirect, and Cochrane databases and extracted hazard ratio (HR) and their corresponding 95% confidence intervals (95% CIs) from eligible studies. Pooled total effect value by the STATA statistical software and analyzed correlation of TAMs with overall survival (OS) and progression-free survival (PFS). Furthermore, subgroup analysis and sensitivity analysis were also conducted.We deemed eleven studies, including 1211 NHL patients. Our study demonstrated that high-density CD68 TAMs is associated with poor OS (HR: 1.17; 95% CI, 0.81-1.54; P=0.000) and poor PFS (HR: 1.15; 95% CI, 0.63-1.67; P=0.000) compared with low-density CD68 TAMs in the tumor microenvironment. Similarly, high-density CD163 TAMs can also predict poor OS (HR: 1.52; 95% CI, 1.11-1.92; P=0.000) and shorter PFS (HR: 1.52; 95% CI, 0.73-2.30; P=0.000). In addition, the high CD163 /CD68 TAMs ratio is significantly correlated with poor OS (HR: 3.59; 95% CI, 0.77-6.40; P=0.013). However, in our subgroup analysis, high-density CD68 TAMs in the tumor microenvironment is associated with better OS (HR: 0.75; 95% CI, 0.41-1.09; P=0.000) in NHL patients treated with rituximab chemotherapy.Our results suggest that TAMs is a robust predictor of outcomes in NHL.
Reference Key
xu2019thescandinavian Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Xu, Xuanxuan;Li, Zhixia;Liu, Jun;Zhu, Fengfeng;Wang, Zhitao;Wang, Jiyu;Zhang, Jiakui;Wang, Huiping;Zhai, Zhimin;
Journal scandinavian journal of immunology
Year 2019
DOI
10.1111/sji.12814
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.